Effect of Dapagliflozin on Alanine Aminotransferase Improvement in Type 2 Diabetes Mellitus with Non-alcoholic Fatty Liver Disease
Dug-Hyun Choi (Choi DH), Chan-Hee Jung (Jung CH), Ji-Oh Mok (Mok JO), Chul-Hee Kim (Kim CH), Sung-Koo Kang (Kang SK), Bo-Yeon Kim (Kim BY)
Endocrinol Metab. 2018;33(3):387-394.   Published online 2018 Sep 18     DOI: https://doi.org/10.3803/EnM.2018.33.3.387
Citations to this article as recorded by Crossref logo
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease
F. Anthony Romero, Christopher T. Jones, Yingzi Xu, Martijn Fenaux, Randall L. Halcomb
Journal of Medicinal Chemistry.2020;[Epub]     CrossRef
SGLT2 Inhibitors in Liver Patients
John Chen Hsiang, Vincent Wai-Sun Wong
Clinical Gastroenterology and Hepatology.2020; 18(10): 2168.     CrossRef
The impact of sodium glucose co‐transporter 2 inhibitors on non‐alcoholic fatty liver disease
Lampros Chrysavgis, Alkistis‐Maria Papatheodoridi, Antonios Chatzigeorgiou, Evangelos Cholongitas
Journal of Gastroenterology and Hepatology.2020;[Epub]     CrossRef
Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics
Stergios A. Polyzos, Jannis Kountouras, Christos S. Mantzoros
Metabolism.2019; 92: 82.     CrossRef
Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment
Kyung-Soo Kim, Byung-Wan Lee, Yong Jin Kim, Dae Ho Lee, Bong-Soo Cha, Cheol-Young Park
Diabetes & Metabolism Journal.2019; 43(2): 127.     CrossRef
Concurrent exercise improves insulin resistance and nonalcoholic fatty liver disease by upregulating PPAR-γ and genes involved in the beta-oxidation of fatty acids in ApoE-KO mice fed a high-fat diet
Fan Zheng, Ying Cai
Lipids in Health and Disease.2019;[Epub]     CrossRef
The Effects of Hypoglycemic Agents on Non-alcoholic Fatty Liver Disease: Focused on Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
Chan-Hee Jung, Ji-Oh Mok
Journal of Obesity & Metabolic Syndrome.2019; 28(1): 18.     CrossRef
Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus?
Niki Katsiki, Nikolaos Perakakis, Christos Mantzoros
Metabolism.2019; 98: iii.     CrossRef
Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress
Tamiris Ingrid Petito-da-Silva, Vanessa Souza-Mello, Sandra Barbosa-da-Silva
Molecular and Cellular Endocrinology.2019; 498: 110539.     CrossRef
Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications
A.J. Scheen
Diabetes & Metabolism.2019; 45(3): 213.     CrossRef